Remove samsung-biologics-national-oncoventure-and-eutilex-obtains-ind-approval-from-fda
article thumbnail

Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

Pharma Mirror

Samsung Biologics (KRX: 207940.KS) KS) announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy, furthering the company’s track record as a premiere CDO service provider in the global market. We are extremely glad to.